OBJECTIVE： To explore the effectiveness and safety of bicyclol combined with ganciclovir in the treatment of infantile cytomegaloirus hepatitis. METHODS： One hundred and twenty children with cytomegaloirus hepatitis in department of pediatrics of our hospital during May 2012-Aug. 2015 were selected and divided into observation group and control group according to random number table， with 60 cases in each group. Both groups received conventional treatment such as protecting liver， vitamin C， vitamin K and Compound glycyrrhizin injection 20 mL， ivgtt， qd. Control group additionally received Ganciclovir injection （induction period： 5 mg/kg，q12 h， dripping time ＞1 h， for 7 d； maintenance period： 5 mg/kg，q24 h，for 7 d）； observation group was additionally given Bicyclol tablet 0.5 mg/kg，bid， on the basis of control group. Clinical efficacies of 2 groups were observed as well as liver enzyme level， jaundice level before and after treatment. The rate of negative CMV and the occurrence of ADR were compared. RESULTS： Clinical total response rate of observation group was 93.3％， which was significantly higher than 80.0％ of control group， with statistical significance （P＜0.05）. There was no statistical significance in liver enzyme level and jaundice level between 2 groups before treatment （P＞0.05）. After treatment， liver enzyme level and jaundice level of 2 groups were decreased significantly， and observation group was significantly lower than control group， with statistical significance （P＜0.05）. The rate of total negative CMV in observation group was 85.0％， which was significantly higher than 73.3％ of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Bicyclol combined with ganciclovir shows significant therapeutic efficacy for infantile cytomegaloirus hepatitis， and can effectively reduce the levels of liver enzymes， eliminate jaundice， protect liver function， promote virus clearance with good safety.